8-K: Annovis Bio Announces CFO Departure and Interim Replacement

Annovis Bio, Inc. has announced the departure of its Chief Financial Officer, Henry Hagopian, effective April 30, 2024, and the appointment of CEO Maria Maccecchini as interim CFO.

Summary

• Annovis Bio's Chief Financial Officer, Henry Hagopian, has stepped down from his position effective April 30, 2024, to pursue other opportunities.
• The resignation was not due to any disagreements with the company's accounting or financial practices.
• Maria Maccecchini, the company's President and CEO, has been appointed as the interim principal financial officer, effective May 1, 2024.
• A separation agreement was reached with Mr. Hagopian, which includes severance benefits.
• The severance package includes two months of base salary ($62,500), two months of medical and dental insurance premium reimbursement ($3,000), immediate vesting of 10,000 stock options, and an extension of the exercise period for other stock options until December 31, 2024.
• Mr. Hagopian must not revoke the separation agreement within seven days and must comply with its terms to receive the severance benefits.

Sentiment

Score: 6

Explanation: The document is neutral in tone, reporting a standard executive departure and transition. While the departure of a CFO is a significant event, the company has taken steps to ensure continuity. The sentiment is therefore slightly positive due to the lack of negative indicators.

Positives

• The transition of the CFO role appears to be amicable, with no indication of disputes or disagreements.
• The company has quickly appointed an interim CFO, ensuring continuity in financial leadership.
• The separation agreement provides clear terms for Mr. Hagopian's departure, including severance benefits and extended stock option exercise periods.

Negatives

• The departure of the CFO creates a temporary gap in the company's financial leadership.
• The company will incur costs associated with the severance package for Mr. Hagopian, totaling $65,500 in cash payments.
• The CEO is now also the interim CFO, which may increase her workload and responsibilities.

Risks

• The interim CFO appointment may create additional workload for the CEO and potentially impact her focus on other strategic initiatives.
• The company may face challenges in finding a suitable permanent replacement for the CFO position.
• There is a risk of disruption in financial operations during the transition period.

Future Outlook

The company will need to find a permanent replacement for the CFO position. The company will continue to operate with the CEO as interim CFO.

Management Comments

• The Board thanks Mr. Hagopian for his service to the Company and wishes him well in his future endeavors.
• Maria Maccecchini has been appointed as the interim principal financial officer.

Industry Context

Executive departures and interim appointments are not uncommon in the biotech industry, especially in smaller companies. This change may be viewed as a normal part of the business cycle, but the market will be watching to see who is appointed as the permanent CFO.

Comparison to Industry Standards

• Severance packages for departing executives typically include a combination of salary continuation, benefits continuation, and stock option vesting or extensions. The package provided to Mr. Hagopian appears to be within industry norms for a CFO departure.
• The appointment of the CEO as interim CFO is a common practice in smaller companies to ensure continuity and control during a transition period. This is similar to other companies such as [Company X] and [Company Y] who have also used this approach in the past.
• The extension of stock option exercise periods is a standard practice to allow departing executives to benefit from their vested options. This is similar to the approach taken by [Company Z] in their recent executive departure.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the departure of the CFO and the potential impact on the company's financial stability.
• Employees may experience some uncertainty during the transition period.
• Creditors and suppliers may monitor the situation to ensure the company's financial health remains stable.

Next Steps

• The company will need to initiate a search for a permanent Chief Financial Officer.
• The company will need to ensure a smooth transition of financial responsibilities to the interim CFO.
• The company will need to comply with the terms of the separation agreement with Mr. Hagopian.

Key Dates

Keywords

CFO, Chief Financial Officer, executive departure, interim CFO, severance agreement, stock options, financial officer, management change, Annovis Bio